Overview

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-04-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Phase:
PHASE1
Details
Lead Sponsor:
GlaxoSmithKline